

CLAIMS

What is claimed is:

1. A method of treating a cancer in a human subject in need thereof with an
5 activatable anti-CTLA-4 antibody, the method comprising administering the
 activatable anti-CTLA-4 antibody once every four weeks (Q4W) or once every
 eight weeks (Q8W);
 wherein the activatable anti-CTLA-4 antibody comprises:
 - 10 a. a heavy chain comprising the heavy chain variable domain sequence of
 SEQ ID NO: 9; and
 - b. a light chain comprising a light chain variable domain sequence selected
 from the group consisting of SEQ ID NOs: 21, 22 and 23.
2. The method of Claim 1 wherein the activatable anti-CTLA-4 antibody comprises:
15 a. a heavy chain comprising the sequence of SEQ ID NO: 11; and
 b. a light chain comprising the sequence of SEQ ID NO: 24.
3. The method of any one of the preceding claims wherein the activatable anti-
CTLA-4 antibody is administered Q8W.
20
4. The method of any one of the preceding claims wherein the activatable anti-
CTLA-4 antibody is administered at a flat dose of 240, 800, 1600 or 2400 mg.
5. The method of Claim 4 wherein the activatable anti-CTLA-4 antibody is
25 administered at a flat dose of 1600 mg Q8W.
6. The method of any one of the preceding claims wherein the cancer is selected
 from the group consisting of:
 - 30 a. unresectable or metastatic melanoma; and
 - b. adjuvant treatment of melanoma.
7. A method of treating a cancer in a human subject in need thereof with an
 activatable anti-CTLA-4 antibody in combination with nivolumab, comprising

administering the activatable anti-CTLA-4 antibody once every four weeks (Q4W) or once every eight weeks (Q8W), wherein the activatable anti-CTLA-4 antibody comprises:

- 5 a. a heavy chain comprising the heavy chain variable domain sequence of SEQ ID NO: 9; and
- b. a light chain comprising a light chain variable domain sequence selected from the group consisting of SEQ ID NOs: 21, 22 and 23.
8. The method of Claim 7 wherein the activatable anti-CTLA-4 antibody comprises:
 - 10 a. a heavy chain comprising the sequence of SEQ ID NO: 11; and
 - b. a light chain comprising the sequence of SEQ ID NO. 24.
9. The method of either of Claim 7 or Claim 8, wherein the activatable anti-CTLA-4 antibody is administered Q8W.
- 15 10. The method of any one of Claims 7 – 9, wherein the activatable anti-CTLA-4 antibody is administered at a flat dose of 240, 600, 800, 1200 or 1600 mg.
11. The method of Claim 10 wherein nivolumab is administered at a flat dose of 480 mg Q4W.
- 20 12. The method of Claim 11 wherein Activatable Ipilimumab is administered at a flat dose of 600 mg Q4W.
13. The method of Claim 11 wherein Activatable Ipilimumab is administered at a flat dose of 1200 mg Q8W.
- 25 14. The method of any one of Claims 7 – 13 wherein the cancer is selected from the group consisting of:
 - 30 a. advanced renal cell carcinoma;
 - b. microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer;
 - c. melanoma;
 - d. non-small cell lung cancer (NSCLC);

- e. malignant pleural mesothelioma; and
- f. hepatocellular carcinoma.